
## Manoel Barral Netto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5183358/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. The Lancet Regional Health Americas, 2022, 6, 100154.	2.6	55
2	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet, The, 2022, 399, 25-35.	13.7	109
3	Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, 2022, 28, 838-843.	30.7	85
4	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infectious Diseases, The, 2022, 22, 791-801.	9.1	84
5	CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study. BMC Medicine, 2022, 20, 146.	5.5	14
6	Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet Infectious Diseases, The, 2022, 22, 945-946.	9.1	32
7	A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> in Brazil. Clinical Infectious Diseases, 2021, 73, e2465-e2469.	5.8	9
8	Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial. International Journal of Infectious Diseases, 2021, 103, 358-363.	3.3	5
9	Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 2021, 371, 288-292.	12.6	412
10	Bridging Learning in Medicine and Citizenship During the COVID-19 Pandemic: A Telehealth-Based Case Study. JMIR Public Health and Surveillance, 2021, 7, e24795.	2.6	11
11	LTB4-Driven Inflammation and Increased Expression of <i>ALOX5</i> / <i>ACE2</i> During Severe COVID-19 in Individuals With Diabetes. Diabetes, 2021, 70, 2120-2130.	0.6	18
12	Anti-chikungunya virus seroprevalence in Indigenous groups in the São Francisco Valley, Brazil. PLoS Neglected Tropical Diseases, 2021, 15, e0009468.	3.0	4
13	Selective Suppression of Cellular Immunity and Increased Cytotoxicity in Skin Lesions of Disseminated Leishmaniasis Uncovered by Transcriptome-Wide Analysis. Journal of Investigative Dermatology, 2021, 141, 2542-2546.e5.	0.7	0
14	Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation. PLoS Neglected Tropical Diseases, 2021, 15, e0009886.	3.0	5
15	Can urbanisation influence alcohol consumption by Indigenous groups? A brief analysis of Brazilian data. Drug and Alcohol Review, 2021, , .	2.1	0
16	Evolution of cytokines/chemokines in cases with communityâ€acquired pneumonia and distinct etiologies. Pediatric Pulmonology, 2020, 55, 169-176.	2.0	10
17	Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence. Parasite Epidemiology and Control, 2020, 8, e00126.	1.8	4
18	Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in L. infantum-infected dogs. Vaccine: X, 2020, 4, 100048.	2.1	11

#	Article	IF	CITATIONS
19	The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19. Respiratory Research, 2020, 21, 178.	3.6	10
20	A clinical scoring system to predict long-term arthralgia in Chikungunya disease: AÂcohort study. PLoS Neglected Tropical Diseases, 2020, 14, e0008467.	3.0	14
21	The re-emergence of Zika in Brazil in 2020: a case of Guillain Barré Syndrome during the low season for arboviral infections. Journal of Travel Medicine, 2020, 27, .	3.0	16
22	Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis. Journal of Immunology Research, 2020, 2020, 1-9.	2.2	5
23	Chronic Hepatitis B Infection Is Associated with Increased Molecular Degree of Inflammatory Perturbation in Peripheral Blood. Viruses, 2020, 12, 864.	3.3	7
24	Oral lesions are frequent in patients with Chikungunya infection. Journal of Travel Medicine, 2020, 27,	3.0	7
25	Investigating associations between intestinal alterations and parasite load according to Bifidobacterium spp. and Lactobacillus spp. abundance in the gut microbiota of hamsters infected by Leishmania infantum. Memorias Do Instituto Oswaldo Cruz, 2020, 115, e200377.	1.6	6
26	Medidas de distanciamento social no controle da pandemia de COVID-19: potenciais impactos e desafios no Brasil. Ciencia E Saude Coletiva, 2020, 25, 2423-2446.	0.5	414
27	Reorganização da atenção primária à saúde para vigilância universal e contenção da COVID-19. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2020, 29, e2020494.	1.0	15
28	Ecocardiografia e Análise de Doenças Cardiovasculares SubclÃnicas em Povos IndÃgenas que Vivem em Diferentes Graus de Urbanização: Projeto de Aterosclerose nas Populações IndÃgenas (Pai). Arquivos Brasileiros De Cardiologia - Imagem Cardiovascular, 2020, 33, 1-8.	0.0	3
29	Echocardiography and Analysis of Subclinical Cardiovascular Diseases in Indigenous People Living in Different Degrees of Urbanization: Project of Atherosclerosis Among Indigenous Populations (Pai). Arquivos Brasileiros De Cardiologia - Imagem Cardiovascular, 2020, 33, .	0.0	0
30	Testes diagnósticos na COVID-19. , 2020, , .		1
31	The Transcriptional and Protein Profile From Human Infected Neuroprogenitor Cells Is Strongly Correlated to Zika Virus Microcephaly Cytokines Phenotype Evidencing a Persistent Inflammation in the CNS. Frontiers in Immunology, 2019, 10, 1928.	4.8	49
32	Chronic hepatitis B virus infection drives changes in systemic immune activation profile in patients coinfected with Plasmodium vivax malaria. PLoS Neglected Tropical Diseases, 2019, 13, e0007535.	3.0	14
33	Determination and Profiling of Human Skin Odors Using Hair Samples. Molecules, 2019, 24, 2964.	3.8	8
34	Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas' disease. International Journal of Infectious Diseases, 2019, 79, 123-130.	3.3	19
35	Presence of parasite DNA in clinically unaffected nasal mucosa during cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Clinical Microbiology and Infection, 2019, 25, 515.e5-515.e7.	6.0	12
36	An open toolkit for tracking open science partnership implementation and impact. Gates Open Research, 2019, 3, 1442.	1.1	10

#	Article	IF	CITATIONS
37	The Center for Data and Knowledge Integration for Health (CIDACS). International Journal of Population Data Science, 2019, 4, 1140.	0.1	30
38	Surveillance of donated blood during the 2016 arbovirus outbreak in Brazil. Journal of Medical Virology, 2018, 90, 1406-1410.	5.0	5
39	Attraction of phlebotomine sandflies to volatiles from skin odors of individuals residing in an endemic area of tegumentary leishmaniasis. PLoS ONE, 2018, 13, e0203989.	2.5	17
40	For socially engaged science: The dynamics of knowledge production in the Fiocruz graduate program in the framework of the "Brazil Without Extreme Poverty Plan". PLoS ONE, 2018, 13, e0204232.	2.5	3
41	Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 112.	3.9	9
42	Lutzomyia longipalpis Saliva Drives Interleukin-17-Induced Neutrophil Recruitment Favoring Leishmania infantum Infection. Frontiers in Microbiology, 2018, 9, 881.	3.5	15
43	Distinct inflammatory profile underlies pathological increases in creatinine levels associated with Plasmodium vivax malaria clinical severity. PLoS Neglected Tropical Diseases, 2018, 12, e0006306.	3.0	20
44	G Protein-Coupled Kinin Receptors and Immunity Against Pathogens. Advances in Immunology, 2017, 136, 29-84.	2.2	16
45	Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 53-63.	1.6	23
46	Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models. PLoS Neglected Tropical Diseases, 2017, 11, e0005644.	3.0	23
47	The microbiological signature of human cutaneous leishmaniasis lesions exhibits restricted bacterial diversity compared to healthy skin. Memorias Do Instituto Oswaldo Cruz, 2016, 111, 241-251.	1.6	28
48	Degranulating Neutrophils Promote Leukotriene B4 Production by Infected Macrophages To Kill <i>Leishmania amazonensis</i> Parasites. Journal of Immunology, 2016, 196, 1865-1873.	0.8	21
49	Zika virus and microcephaly in Brazil: a scientific agenda. Lancet, The, 2016, 387, 919-921.	13.7	50
50	Gene Expression Profile of High IFN-γ Producers Stimulated with Leishmania braziliensis Identifies Genes Associated with Cutaneous Leishmaniasis. PLoS Neglected Tropical Diseases, 2016, 10, e0005116.	3.0	29
51	Revisiting the Heterogeneous IFN-Î <sup>3</sup> Response of Bacille of Calmette-Guérin (BCG)-Revaccinated Healthy Volunteers in a Randomized Controlled Trial: Effect of the Body Mass Index and of the IFNG+874 A/T Polymorphism. PLoS ONE, 2016, 11, e0160149.	2.5	5
52	Unravelling the patterns of host immune responses in Plasmodium vivax malaria and dengue co-infection. Malaria Journal, 2015, 14, 315.	2.3	26
53	Associations between hepcidin and immune response in individuals with hyperbilirubinaemia and severe malaria due to Plasmodium vivax infection. Malaria Journal, 2015, 14, 407.	2.3	6
54	Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. British Journal of Clinical Pharmacology, 2015, 80, 1160-1168.	2.4	15

#	Article	IF	CITATIONS
55	Immunoregulation in human malaria: the challenge of understanding asymptomatic infection. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 945-955.	1.6	31
56	Prediction of CD8+ Epitopes in Leishmania braziliensis Proteins Using EPIBOT: In Silico Search and In Vivo Validation. PLoS ONE, 2015, 10, e0124786.	2.5	15
57	Differential Gene Expression and Infection Profiles of Cutaneous and Mucosal Leishmania braziliensis Isolates from the Same Patient. PLoS Neglected Tropical Diseases, 2015, 9, e0004018.	3.0	44
58	Medical Specialty Choice and Related Factors of Brazilian Medical Students and Recent Doctors. PLoS ONE, 2015, 10, e0133585.	2.5	35
59	Vaccination with Leishmania infantum Acidic Ribosomal PO but Not with Nucleosomal Histones Proteins Controls Leishmania infantum Infection in Hamsters. PLoS Neglected Tropical Diseases, 2015, 9, e0003490.	3.0	11
60	Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice. PLoS Neglected Tropical Diseases, 2015, 9, e0003751.	3.0	16
61	Proteome Profiling of Human Cutaneous Leishmaniasis Lesion. Journal of Investigative Dermatology, 2015, 135, 400-410.	0.7	40
62	Arginase I, Polyamine, and Prostaglandin E <sub>2</sub> Pathways Suppress the Inflammatory Response and Contribute to Diffuse Cutaneous Leishmaniasis. Journal of Infectious Diseases, 2015, 211, 426-435.	4.0	73
63	Corrections to: "CD8+ Granzyme B+–Mediated Tissue Injury versus CD4+IFNγ+–Mediated Parasite Killing in Human Cutaneous Leishmaniasis― Journal of Investigative Dermatology, 2014, 134, 2850.	0.7	0
64	Serological survey of Leishmaniainfection in blood donors in Salvador, Northeastern Brazil. BMC Infectious Diseases, 2014, 14, 422.	2.9	22
65	DDX39B (BAT1), TNF and IL6 gene polymorphisms and association with clinical outcomes of patients with Plasmodium vivax malaria. Malaria Journal, 2014, 13, 278.	2.3	33
66	SOD1 Plasma Level as a Biomarker for Therapeutic Failure in Cutaneous Leishmaniasis. Journal of Infectious Diseases, 2014, 210, 306-310.	4.0	22
67	Dual effect of Lutzomyia longipalpis saliva on Leishmania braziliensis infection is mediated by distinct saliva-induced cellular recruitment into BALB/c mice ear. BMC Microbiology, 2013, 13, 102.	3.3	22
68	Networking the host immune response in Plasmodium vivax malaria. Malaria Journal, 2013, 12, 69.	2.3	59
69	267. Cytokine, 2013, 63, 306.	3.2	1
70	Seroconversion of sentinel chickens as a biomarker for monitoring exposure to visceral Leishmaniasis. Scientific Reports, 2013, 3, 2352.	3.3	15
71	PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 985-995.	3.3	41
72	CD8+ Granzyme B+–Mediated Tissue Injury vs. CD4+IFNγ+–Mediated Parasite Killing in Human Cutaneous Leishmaniasis. Journal of Investigative Dermatology, 2013, 133, 1533-1540.	0.7	125

#	Article	IF	CITATIONS
73	Serum cytokines associated with severity and complications of kala-azar. Pathogens and Global Health, 2013, 107, 78-87.	2.3	87
74	Functional Transcriptomics of Wild-Caught Lutzomyia intermedia Salivary Glands: Identification of a Protective Salivary Protein against Leishmania braziliensis Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2242.	3.0	60
75	In vitro study of the photodynamic antimicrobial therapy (PACT) against promastigotes form of theleishmania (viannia) braziliensis: in vitro study. , 2013, , .		2
76	Analysis of theoretical knowledge and the practice of science among brazilian otorhinolaryngologists. Brazilian Journal of Otorhinolaryngology, 2013, 79, 487-493.	1.0	2
77	Challenges in the research and development of new human vaccines. Brazilian Journal of Medical and Biological Research, 2013, 46, 103-108.	1.5	5
78	Experimental Infection of Dogs with Leishmania and Saliva as a Model to Study Canine Visceral Leishmaniasis. PLoS ONE, 2013, 8, e60535.	2.5	30
79	Towards a More Precise Serological Diagnosis of Human Tegumentary Leishmaniasis Using Leishmania Recombinant Proteins. PLoS ONE, 2013, 8, e66110.	2.5	41
80	The Host Genetic Diversity in Malaria Infection. Journal of Tropical Medicine, 2012, 2012, 1-17.	1.7	41
81	Association between the Haptoglobin and Heme Oxygenase 1 Genetic Profiles and Soluble CD163 in Susceptibility to and Severity of Human Malaria. Infection and Immunity, 2012, 80, 1445-1454.	2.2	70
82	Immunodominant Antigens of Leishmania chagasi Associated with Protection against Human Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2012, 6, e1687.	3.0	13
83	Heme Oxygenase-1 Promotes the Persistence of <i>Leishmania chagasi</i> Infection. Journal of Immunology, 2012, 188, 4460-4467.	0.8	87
84	Evaluation of photodynamic antimicrobial therapy (PACT) against promastigotes form of the Leishmania (Viannia) braziliensis : in vitro study. Proceedings of SPIE, 2012, , .	0.8	1
85	Metabolic Adaptation to Tissue Iron Overload Confers Tolerance to Malaria. Cell Host and Microbe, 2012, 12, 693-704.	11.0	123
86	Photodynamic antimicrobial chemotherapy (PACT) using phenothiazine derivatives as photosensitizers against <i>Leishmania braziliensis</i> . Lasers in Surgery and Medicine, 2012, 44, 850-855.	2.1	35
87	Vaccination with L. infantum chagasi Nucleosomal Histones Confers Protection against New World Cutaneous Leishmaniasis Caused by Leishmania braziliensis. PLoS ONE, 2012, 7, e52296.	2.5	16
88	New Insights on the Inflammatory Role ofLutzomyia longipalpisSaliva in Leishmaniasis. Journal of Parasitology Research, 2012, 2012, 1-11.	1.2	18
89	Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 735-739.	1.6	49
90	Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. International Journal of Nanomedicine, 2012, 7, 2115.	6.7	25

#	Article	IF	CITATIONS
91	Stimulating the Formation of the Physician-Scientist; Scientific Exposure during the Medical Course in Brazil. Medical Science Educator, 2011, 21, 107-111.	1.5	1
92	Lesion Size Correlates with Leishmania Antigen-Stimulated TNF-Levels in Human Cutaneous Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 2011, 85, 70-73.	1.4	66
93	<i>Lutzomyia longipalpis</i> saliva drives apoptosis and enhances parasite burden in neutrophils. Journal of Leukocyte Biology, 2011, 90, 575-582.	3.3	55
94	DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis. Acta Tropica, 2011, 120, 185-190.	2.0	28
95	Hormone levels are associated with clinical markers and cytokine levels in human localized cutaneous leishmaniasis. Brain, Behavior, and Immunity, 2011, 25, 548-554.	4.1	17
96	Characterization of TcSTI-1, a homologue of stress-induced protein-1, in Trypanosoma cruzi. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 70-77.	1.6	12
97	Biomarkers for susceptibility to infection and disease severity in human malaria. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 70-78.	1.6	29
98	Can Score Databanks Help Teaching?. PLoS ONE, 2011, 6, e15695.	2.5	0
99	TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infection, Genetics and Evolution, 2011, 11, 912-916.	2.3	37
100	Lutzomyia longipalpis Saliva or Salivary Protein LJM19 Protects against Leishmania braziliensis and the Saliva of Its Vector, Lutzomyia intermedia. PLoS Neglected Tropical Diseases, 2011, 5, e1169.	3.0	60
101	Hepatitis B Infection Is Associated with Asymptomatic Malaria in the Brazilian Amazon. PLoS ONE, 2011, 6, e19841.	2.5	56
102	Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1) Tj ETQqC Hematology, 2010, 89, 877-882.	0 0 rgBT 1.8	/Overlock 10 33
103	<i>Mycobacterium tuberculosis</i> Rv1419 encodes a secreted 13 kDa lectin with immunological reactivity during human tuberculosis. European Journal of Immunology, 2010, 40, 744-753.	2.9	11
104	Human mucosal leishmaniasis: Neutrophils infiltrate areas of tissue damage that express high levels of Th17â€related cytokines. European Journal of Immunology, 2010, 40, 2830-2836.	2.9	114
105	In vitro initial immune response against Leishmania amazonensis infection is characterized by an increased production of IL-10 and IL-13. Brazilian Journal of Infectious Diseases, 2010, 14, 476-482.	0.6	1
106	Research knowledge in undergraduate school in Brazil: a comparison between medical and law students. Einstein (Sao Paulo, Brazil), 2010, 8, 273-280.	0.7	4
107	Epidemiological Study of the Association between Anti-Lutzomyia longipalpis Saliva Antibodies and Development of Delayed-Type Hypersensitivity to Leishmania Antigen. American Journal of Tropical Medicine and Hygiene, 2010, 83, 825-827.	1.4	20
108	Using Recombinant Proteins from Lutzomyia longipalpis Saliva to Estimate Human Vector Exposure in Visceral Leishmaniasis Endemic Areas. PLoS Neglected Tropical Diseases, 2010, 4, e649.	3.0	72

#	Article	IF	CITATIONS
109	Plasma Superoxide Dismutase-1 as a Surrogate Marker of Vivax Malaria Severity. PLoS Neglected Tropical Diseases, 2010, 4, e650.	3.0	43
110	Immunity to Lutzomyia intermedia Saliva Modulates the Inflammatory Environment Induced by Leishmania braziliensis. PLoS Neglected Tropical Diseases, 2010, 4, e712.	3.0	54
111	BALB/c Mice Vaccinated withLeishmania majorRibosomal Proteins Extracts Combined with CpG Oligodeoxynucleotides Become Resistant to Disease Caused by a Secondary Parasite Challenge. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9.	3.0	19
112	In vitro initial immune response against Leishmania amazonensis infection is characterized by an increased production of IL-10 and IL-13. Brazilian Journal of Infectious Diseases, 2010, 14, 476-482.	0.6	6
113	Heme Impairs Prostaglandin E2 and TGF-β Production by Human Mononuclear Cells via Cu/Zn Superoxide Dismutase: Insight into the Pathogenesis of Severe Malaria. Journal of Immunology, 2010, 185, 1196-1204.	0.8	50
114	Chemokines and chemokine receptors coordinate the inflammatory immune response in human cutaneous leishmaniasis. Human Immunology, 2010, 71, 1220-1227.	2.4	32
115	Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clinica Chimica Acta, 2010, 411, 540-545.	1.1	55
116	Artificial Neural Networks and Bayesian Networks as supportting tools for diagnosis of asymptomatic malaria. , 2010, , .		5
117	Towards a precise test for malaria diagnosis in the Brazilian Amazon: comparison among field microscopy, a rapid diagnostic test, nested PCR, and a computational expert system based on artificial neural networks. Malaria Journal, 2010, 9, 117.	2.3	61
118	Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malaria Journal, 2010, 9, 13.	2.3	217
119	DETC Induces Leishmania Parasite Killing in Human In Vitro and Murine In Vivo Models: A Promising Therapeutic Alternative in Leishmaniasis. PLoS ONE, 2010, 5, e14394.	2.5	40
120	In vitro initial immune response against Leishmania amazonensis infection is characterized by an increased production of IL-10 and IL-13. Brazilian Journal of Infectious Diseases, 2010, 14, 476-82.	0.6	2
121	Could the lower frequency of CD8+CD18+CD45RO+ lymphocytes be biomarkers of human VL?. International Immunology, 2009, 21, 137-144.	4.0	13
122	Neutrophils and Macrophages Cooperate in Host Resistance against <i>Leishmania braziliensis</i> Infection. Journal of Immunology, 2009, 183, 8088-8098.	0.8	121
123	IFN-β Impairs Superoxide-Dependent Parasite Killing in Human Macrophages: Evidence for a Deleterious Role of SOD1 in Cutaneous Leishmaniasis. Journal of Immunology, 2009, 182, 2525-2531.	0.8	85
124	Challenges and perspectives in vaccination against leishmaniasis. Parasitology International, 2009, 58, 319-324.	1.3	36
125	Anti-Anopheles darlingi saliva antibodies as marker of Plasmodium vivax infection and clinical immunity in the Brazilian Amazon. Malaria Journal, 2009, 8, 121.	2.3	59
126	Searching Genes Encoding Leishmania Antigens for Diagnosis and Protection. Scholarly Research Exchange, 2009, 2009, 1-25.	0.2	13

#	Article	IF	CITATIONS
127	The Value of the Otorhinolaryngologic Exam in Correct Mucocutaneous Leishmaniasis Diagnosis. American Journal of Tropical Medicine and Hygiene, 2009, 81, 384-386.	1.4	6
128	Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes and Infection, 2008, 10, 1133-1141.	1.9	56
129	Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathology Research and Practice, 2008, 204, 155-161.	2.3	72
130	Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis. Clinical and Experimental Immunology, 2008, 102, 535-540.	2.6	15
131	Immunomodulation of human monocytes following exposure to Lutzomyia intermedia saliva. BMC Immunology, 2008, 9, 12.	2.2	16
132	Potential immunomodulatory effects of plant lectins in Schistosoma mansoni infection. Acta Tropica, 2008, 108, 160-165.	2.0	16
133	Changes in Amounts of Total Salivary Gland Proteins of Lutzomyia longipalpis (Diptera: Psychodidae) According to Age and Diet. Journal of Medical Entomology, 2008, 45, 409-413.	1.8	34
134	Interactions with apoptotic but not with necrotic neutrophils increase parasite burden in human macrophages infected with <i>Leishmania amazonensis</i> . Journal of Leukocyte Biology, 2008, 84, 389-396.	3.3	76
135	Changes in Amounts of Total Salivary Gland Proteins of <i>Lutzomyia longipalpis</i> (Diptera:) Tj ETQq1 1 0.784	314 rgBT / 1.8	Oygrlock 10
136	<i>Leishmania amazonensis</i> infection impairs differentiation and function of human dendritic cells. Journal of Leukocyte Biology, 2007, 82, 1401-1406.	3.3	60
137	Enhanced Leishmania braziliensis Infection Following Pre-Exposure to Sandfly Saliva. PLoS Neglected Tropical Diseases, 2007, 1, e84.	3.0	82
138	Human antiâ€ <b>s</b> aliva immune response following experimental exposure to the visceral leishmaniasis vector, <i>Lutzomyia longipalpis</i> . European Journal of Immunology, 2007, 37, 3111-3121.	2.9	73
139	Role of Sand Fly Saliva in Human and Experimental Leishmaniasis: Current Insights. Scandinavian Journal of Immunology, 2007, 66, 122-127.	2.7	84
140	Cellular Analysis of Cutaneous Leishmaniasis Lymphadenopathy: Insights into the Early Phases of Human Disease. American Journal of Tropical Medicine and Hygiene, 2007, 77, 854-859.	1.4	28
141	Are there differences in clinical and laboratory parameters between children and adults with American visceral leishmaniasis?. Acta Tropica, 2006, 97, 252-258.	2.0	21
142	Potential of KM+ lectin in immunization against Leishmania amazonensis infection. Vaccine, 2006, 24, 3001-3008.	3.8	52
143	Correlation between interleukin-10 and in situ necrosis and fibrosis suggests a role for interleukin-10 in the resolution of the granulomatous response of tuberculous pleurisy patients. Microbes and Infection, 2006, 8, 889-897.	1.9	5
144	Chemokines in host–parasiteinteractions in leishmaniasis. Trends in Parasitology, 2006, 22, 32-40.	3.3	110

#	Article	IF	CITATIONS
145	CD4+CD25+T Cells in Skin Lesions of Patients with Cutaneous Leishmaniasis Exhibit Phenotypic and Functional Characteristics of Natural Regulatory T Cells. Journal of Infectious Diseases, 2006, 193, 1313-1322.	4.0	156
146	CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data. Journal of Leukocyte Biology, 2006, 79, 36-39.	3.3	41
147	Characterization of the T-Cell Receptor Vβ Repertoire in the Human Immune Response against Leishmania Parasites. Infection and Immunity, 2006, 74, 4757-4765.	2.2	21
148	CONCOMITANT EARLY MUCOSAL AND CUTANEOUS LEISHMANIASIS IN BRAZIL. American Journal of Tropical Medicine and Hygiene, 2006, 75, 267-269.	1.4	35
149	Concomitant early mucosal and cutaneous leishmaniasis in Brazil. American Journal of Tropical Medicine and Hygiene, 2006, 75, 267-9.	1.4	17
150	Role of costimulatory molecules in immune response of patients with cutaneous leishmaniasis. Microbes and Infection, 2005, 7, 86-92.	1.9	13
151	Balance of IL-10 and Interferon-Î <sup>3</sup> plasma levels in human visceral leishmaniasis: Implications in the pathogenesis. BMC Infectious Diseases, 2005, 5, 113.	2.9	129
152	Haematophagous arthropod saliva and host defense system: a tale of tear and blood. Anais Da Academia Brasileira De Ciencias, 2005, 77, 665-693.	0.8	85
153	Distinct Leishmania braziliensis Isolates Induce Different Paces of Chemokine Expression Patterns. Infection and Immunity, 2005, 73, 1191-1195.	2.2	46
154	Saliva from <i>Lutzomyia longipalpis</i> Induces CC Chemokine Ligand 2/Monocyte Chemoattractant Protein-1 Expression and Macrophage Recruitment. Journal of Immunology, 2005, 175, 8346-8353.	0.8	77
155	INFLAMMATORY CELL INFILTRATION AND HIGH ANTIBODY PRODUCTION IN BALB/c MICE CAUSED BY NATURAL EXPOSURE TO LUTZOMYIA LONGIPALPIS BITES. American Journal of Tropical Medicine and Hygiene, 2005, 72, 94-98.	1.4	54
156	Inflammatory cell infiltration and high antibody production in BALB/c mice caused by natural exposure to Lutzomyia longipalpis bites. American Journal of Tropical Medicine and Hygiene, 2005, 72, 94-8.	1.4	31
157	Lutzomyia longipalpis Salivary Gland Homogenate Impairs Cytokine Production and Costimulatory Molecule Expression on Human Monocytes and Dendritic Cells. Infection and Immunity, 2004, 72, 1298-1305.	2.2	59
158	Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infectious Diseases, 2004, 4, 50.	2.9	57
159	Leishmania braziliensis isolates differing at the genome level display distinctive features in BALB/c mice. Microbes and Infection, 2004, 6, 977-984.	1.9	42
160	Vaccines in leishmaniasis: advances in the last five years. Expert Review of Vaccines, 2003, 2, 705-717.	4.4	33
161	Adhesion molecule expression patterns indicate activation and recruitment of CD4+ T cells from the lymph node to the peripheral blood of early cutaneous leishmaniasis patients. Immunology Letters, 2003, 90, 155-159.	2.5	19
162	Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage. International Journal for Parasitology, 2003, 33, 153-162.	3.1	40

#	Article	IF	CITATIONS
163	Egg Yolk Anti-BfpA Antibodies as a Tool for Recognizing and Identifying Enteropathogenic Escherichia coli. Scandinavian Journal of Immunology, 2003, 57, 573-582.	2.7	19
164	BCG (Bacille of Calmette?Gu�rin) revaccination leads to improved in vitro IFN-\$gamma; response to mycobacterial antigen independent of tuberculin sensitization in Brazilian school-age children. Vaccine, 2003, 21, 2152-2160.	3.8	19
165	Leishmanial infection: analysis of its first steps. A review. Memorias Do Instituto Oswaldo Cruz, 2003, 98, 861-870.	1.6	78
166	Glycoinositolphospholipids from Trypanosoma cruzi Interfere with Macrophages and Dendritic Cell Responses. Infection and Immunity, 2002, 70, 3736-3743.	2.2	73
167	The Replication of Human Immunodeficiency Virus Type 1 in Macrophages Is Enhanced after Phagocytosis of Apoptotic Cells. Journal of Infectious Diseases, 2002, 185, 1561-1566.	4.0	53
168	Seroconversion againstLutzomyia longipalpisSaliva Concurrent with the Development of Anti–Leishmania chagasiDelayedâ€īype Hypersensitivity. Journal of Infectious Diseases, 2002, 186, 1530-1534.	4.0	113
169	Frequency of Infection of Lutzomyia Phlebotomines with Leishmania braziliensis in a Brazilian Endemic Area as Assessed by Pinpoint Capture and Polymerase Chain Reaction. Memorias Do Instituto Oswaldo Cruz, 2002, 97, 185-188.	1.6	65
170	Expression and Purification of the Recombinant Conbr (Canavalia Brasiliensis Lectin) Produced in Escherichia Coli Cells. Protein and Peptide Letters, 2002, 9, 59-66.	0.9	12
171	B-cell infiltration and frequency of cytokine producing cells differ between localized and disseminated human cutaneous leishmaniases. Memorias Do Instituto Oswaldo Cruz, 2002, 97, 979-983.	1.6	26
172	Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microbes and Infection, 2002, 4, 23-29.	1.9	74
173	Characterizing Subpopulations of Neoplastic Cells in Serous Effusions. Acta Cytologica, 2001, 45, 18-22.	1.3	21
174	In vivo lymphocyte activation and apoptosis by lectins of the Diocleinae subtribe. Memorias Do Instituto Oswaldo Cruz, 2001, 96, 673-678.	1.6	49
175	IFN-β and TGF-β differentially regulate IL-12 activity in human peripheral blood mononuclear cells. Immunology Letters, 2001, 75, 117-122.	2.5	9
176	Flow Cytometric Determination of Cellular Sources and Frequencies of Key Cytokine-Producing Lymphocytes Directed against Recombinant LACK and Soluble Leishmania Antigen in Human Cutaneous Leishmaniasis. Infection and Immunity, 2001, 69, 3232-3239.	2.2	109
177	Differences in Gamma Interferon Production In Vitro Predict the Pace of the In Vivo Response to Leishmania amazonensis in Healthy Volunteers. Infection and Immunity, 2001, 69, 7453-7460.	2.2	50
178	Revisiting proteus: Do Minor Changes in Lectin Structure Matter in Biological Activity? Lessons from and Potential Biotechnological Uses of the Diocleinae Subtribe Lectins. Current Protein and Peptide Science, 2001, 2, 123-135.	1.4	112
179	Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death. Journal of Leukocyte Biology, 2001, 70, 745-8.	3.3	23
180	A simple method for human peripheral blood monocyte Isolation. Memorias Do Instituto Oswaldo Cruz, 2000, 95, 221-223.	1.6	109

#	Article	IF	CITATIONS
181	Human immune response to sand fly salivary gland antigens: a useful epidemiological marker?. American Journal of Tropical Medicine and Hygiene, 2000, 62, 740-745.	1.4	141
182	Impacto de múltiplas biópsias em dois pontos distintos da superfÃcie pleural no diagnóstico de tuberculose. Jornal De Pneumologia, 2000, 26, 55-60.	0.1	1
183	A dhfr-ts- Leishmania major Knockout Mutant Cross-protects against Leishmania amazonensis. Memorias Do Instituto Oswaldo Cruz, 1999, 94, 491-496.	1.6	44
184	Lectin-Induced Nitric Oxide Production. Cellular Immunology, 1999, 194, 98-102.	3.0	79
185	Expression of a pilin subunit BfpA of the bundle-forming pilus of enteropathogenic Escherichia coli in an aroA live salmonella vaccine strain. Vaccine, 1999, 17, 770-778.	3.8	19
186	Immunochemotherapy with interferon-Î <sup>3</sup> and multidrug therapy for multibacillary leprosy. Acta Tropica, 1999, 72, 185-201.	2.0	11
187	Cell-mediated immune responses and cytotoxicity to mycobacterial antigens in patients with tuberculous pleurisy in Brazil. Acta Tropica, 1998, 71, 1-15.	2.0	9
188	Human_Leishmaniasis@cytokines.bahia.br. Brazilian Journal of Medical and Biological Research, 1998, 31, 149-155.	1.5	17
189	Production of host-protective (IFN-gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF-alpha) cytokines by PBMC from leprosy patients stimulated with mycobacterial antigens. European Journal of Dermatology, 1998, 8, 98-103.	0.6	1
190	Molecular Cloning and Characterization of ConBr, the Lectin of Canavalia Brasiliensis Seeds. FEBS Journal, 1997, 248, 43-48.	0.2	28
191	Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. Journal of Immunology, 1997, 159, 4467-73.	0.8	70
192	In vivo protective effect of the lectin from Canavalia brasiliensis on BALB/c mice infected by Leishmania amazonensis. Acta Tropica, 1996, 60, 237-250.	2.0	42
193	Interleukin-12 Restores Interferon-Â Production and Cytotoxic Responses in Visceral Leishmaniasis. Journal of Infectious Diseases, 1996, 173, 1515-1518.	4.0	108
194	Variation of Cytokine Patterns Related to Therapeutic Response in Diffuse Cutaneous Leishmaniasis. Experimental Parasitology, 1996, 84, 188-194.	1.2	56
195	Cytotoxicity in patients with different clinical forms of Chagas' disease. Clinical and Experimental Immunology, 1996, 105, 450-455.	2.6	15
196	Biological Behavior of Leishmania amazonensis Isolated from Humans with Cutaneous, Mucosal, or Visceral Leishmaniasis in Balb/C Mice. American Journal of Tropical Medicine and Hygiene, 1996, 54, 178-184.	1.4	71
197	Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunology, 1995, 17, 21-28.	1.5	53
198	POLAR AND SUBPOLAR DIFFUSE CUTANEOUS LEISHMANIASIS IN BRAZIL: CLINICAL AND IMMUNOPATHOLOGIC ASPECTS. International Journal of Dermatology, 1995, 34, 474-479.	1.0	73

#	Article	IF	CITATIONS
199	Lymphadenopathy as the First Sign of Human Cutaneous Infection by Leishmania braziliensis. American Journal of Tropical Medicine and Hygiene, 1995, 53, 256-259.	1.4	89
200	Up-regulation of T helper 2 and down-regulation of T helper 1 cytokines during murine retrovirus-induced immunodeficiency syndrome enhances susceptibility of a resistant mouse strain to Leishmania amazonensis. American Journal of Pathology, 1995, 146, 635-42.	3.8	22
201	Transforming growth factor-beta in human cutaneous leishmaniasis. American Journal of Pathology, 1995, 147, 947-54.	3.8	71
202	Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis Proceedings of the United States of America, 1993, 90, 3442-3446.	7.1	189
203	Human T-Cell Responses in Leishmania Infections. , 1993, 3, 119-144.		9
204	Aggravation of Both Trypanosoma Cruzi and Murine Leukemia Virus by Concomitant Infections. American Journal of Tropical Medicine and Hygiene, 1993, 49, 589-597.	1.4	33
205	Antigen-reactive gamma delta T cells in human leishmaniasis. Journal of Immunology, 1993, 151, 3712-8.	0.8	63
206	Diminished In Vitro Production of Interleukin-1 and Tumor Necrosis Factor-α during Acute Visceral Leishmaniasis and Recovery after Therapy. Journal of Infectious Diseases, 1992, 165, 1094-1102.	4.0	36
207	Human Lymphocyte Stimulation by Legume Lectins from the Diocleae Tribe. Immunological Investigations, 1992, 21, 297-303.	2.0	65
208	Immunologic Markers of Clinical Evolution in Children Recently Infected with Leishmania donovani chagasi. Journal of Infectious Diseases, 1992, 165, 535-540.	4.0	154
209	Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science, 1992, 257, 545-548.	12.6	440
210	Leishmania amazonensis infection: A comparison of in vivo leishmanicidal mechanisms between immunized and naive infected BALB/c mice. Experimental Parasitology, 1992, 74, 169-176.	1.2	8
211	T-lymphocytes in experimentalLeishmania amazonensis infection: comparison between immunized and naive BALB/c mice. Zeitschrift FÃ1⁄4r Parasitenkunde (Berlin, Germany), 1992, 78, 16-22.	0.8	8
212	DIFFUSE CUTANEOUS LEISHMANIASIS WITH ATYPICAL ASPECTS. International Journal of Dermatology, 1992, 31, 568-570.	1.0	11
213	Lymphadenopathy Associated with Leishmania braziliensis Cutaneous Infection. American Journal of Tropical Medicine and Hygiene, 1992, 47, 587-592.	1.4	45
214	Serum kinetics of crotoxin from Crotalus durissus terrificus venom in mice: evidence for a rapid clearance. Toxicon, 1991, 29, 527-531.	1.6	28
215	Granulocytes in the inflammatory process of BALB/c mice infected by Leishmania amazonensis. A quantitative approach. Acta Tropica, 1991, 48, 185-193.	2.0	42
216	Variations in susceptibility to Leishmania amazonensis infection in lines of mice selected for high or low immunoresponsiveness. Parasite Immunology, 1991, 13, 639-647.	1.5	3

#	Article	IF	CITATIONS
217	Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis. Journal of Infectious Diseases, 1991, 163, 853-857.	4.0	105
218	Leishmaniasis in Bahia, Brazil: Evidence that Leishmania amazonensis Produces a Wide Spectrum of Clinical Disease. American Journal of Tropical Medicine and Hygiene, 1991, 44, 536-546.	1.4	300
219	Serum Levels of Bothropic Venom in Patients without Antivenom Intervention. American Journal of Tropical Medicine and Hygiene, 1991, 45, 751-754.	1.4	15
220	Immunological studies with the venom of the scorpion Tityus serrulatus. Brazilian Journal of Medical and Biological Research, 1991, 24, 171-80.	1.5	1
221	Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. Journal of Immunology, 1991, 147, 281-4.	0.8	54
222	Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma. New England Journal of Medicine, 1990, 322, 16-21.	27.0	306
223	Enzyme-linked immunosorbent assay for the detection of Bothrops jararaca venom. Toxicon, 1990, 28, 1053-1061.	1.6	38
224	Serum interferon activity of patients with leishmaniasis. Brazilian Journal of Medical and Biological Research, 1989, 22, 1485-7.	1.5	3
225	Evaluation of T-cell subsets in the lesion infiltrates of human cutaneous and mucocutaneous leishmaniasis. Parasite Immunology, 1987, 9, 487-497.	1.5	26
226	Immunology of human visceral leishmaniasis and perspective of the use of immunomodulators. Memorias Do Instituto Oswaldo Cruz, 1987, 82, 137-146.	1.6	2
227	Destruction of Leishmania mexicana amazonensis Promastigotes by Normal Human Serum. American Journal of Tropical Medicine and Hygiene, 1987, 37, 53-56.	1.4	12
228	Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes. Clinical and Experimental Immunology, 1987, 67, 11-9.	2.6	16
229	Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice. American Journal of Pathology, 1987, 127, 271-8.	3.8	20
230	A simple method for assessing the binding of concanavalin A to mononuclear cell surfaces: no interference of visceral leishmaniasis serum on this binding. Memorias Do Instituto Oswaldo Cruz, 1986, 81, 343-345.	1.6	4
231	Isolation of Leishmania Mexicana Amazonensis from the Bone Marrow in a Case of American Visceral Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 1986, 35, 732-734.	1.4	66
232	Suppression of Lymphocyte Proliferative Responses by Sera from Patients with American Visceral Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 1986, 35, 735-742.	1.4	32
233	Fibroblast stimulating activity of extracts of hepatic granulomata of Schistosoma mansoni-infected rodents with marked or slight hepatic fibrosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, 79, 319-321.	1.8	3
234	Enhancement of the Autologous Mixed Lymphocyte Reaction in Patients with Chagas' Heart Disease *. American Journal of Tropical Medicine and Hygiene, 1984, 33, 1078-1083.	1.4	2

#	Article	IF	CITATIONS
235	Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. Journal of Immunology, 1984, 132, 3116-9.	0.8	22
236	Specificity of Antibody and Cellular Immune Responses in Human Schistosomiasis *. American Journal of Tropical Medicine and Hygiene, 1983, 32, 106-113.	1.4	10
237	Cell-Mediated and Humoral Immune Responses in Capuchin Monkeys Infected with Schistosoma Japonicum or Schistosoma Mansoni *. American Journal of Tropical Medicine and Hygiene, 1983, 32, 1335-1343.	1.4	6
238	Parasitological and Pathological Findings in Capuchin Monkeys Infected with Schistosoma Japonicum or Schistosoma Mansoni. American Journal of Tropical Medicine and Hygiene, 1982, 31, 983-987.	1.4	6
239	Schistosoma mekongi infection in man: cellular immune responses and modulating mechanisms. Clinical and Experimental Immunology, 1982, 47, 65-73.	2.6	2
240	Malignant transformation of a rat fibroma by the treatment with an anti-fibrosing drug: CY-168F (Plastenan). Memorias Do Instituto Oswaldo Cruz, 1981, 76, 259-268.	1.6	0
241	An open toolkit for tracking open science partnership implementation and impact. Gates Open Research, 0, 3, 1442.	1.1	2
242	Tucuxi-BLAST: Enabling fast and accurate record linkage of large-scale health-related administrative databases through a DNA-encoded approach. PeerJ, 0, 10, e13507.	2.0	0